Profile data is unavailable for this security.
About the company
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.
- Revenue in USD (TTM)0.00
- Net income in USD-3.00k
- Incorporated2020
- Employees5.00
- LocationAeon Biopharma Inc5 Park Plaza, Suite 1750IRVINE 92614United StatesUSA
- Phone+1 (949) 354-6499
- Fax+1 (302) 655-5049
- Websitehttps://aeonbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Skye Bioscience Inc | 0.00 | -51.23m | 23.09m | -- | -- | 0.6798 | -- | -- | -1.29 | -1.29 | 0.00 | 1.06 | 0.00 | -- | -- | -- | -83.39 | -139.20 | -94.11 | -262.81 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.43 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -47.58m | 23.20m | 34.00 | -- | 2.86 | -- | -- | -2.80 | -2.80 | 0.00 | 0.3089 | 0.00 | -- | -- | 0.00 | -86.19 | -50.97 | -106.55 | -57.59 | -- | -- | -- | -2,565.78 | -- | -- | 0.00 | -- | -100.00 | -- | 36.71 | -- | -58.03 | -- |
| Regentis Biomaterials Ltd | 0.00 | -5.20m | 23.88m | -- | -- | -- | -- | -- | -1.00 | -1.00 | 0.00 | -1.87 | 0.00 | -- | -- | -- | -1,548.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 226.60 | -- | -- | -- |
| LAMY | 0.00 | 106.70k | 24.50m | -- | 25.51 | -- | 201.80 | -- | 0.0137 | 0.0137 | 0.00 | -0.0045 | 0.00 | -- | -- | -- | 763.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -67.39 | -- | 299.15 | -- | -- | -- |
| Lunai Bioworks Inc | 0.00 | -130.98m | 24.84m | 29.00 | -- | -- | -- | -- | -7.51 | -7.51 | 0.00 | -0.5626 | 0.00 | -- | -- | 0.00 | -203.39 | -75.79 | -304.47 | -85.18 | -- | -- | -- | -- | -- | -28.85 | -- | -- | -- | -- | -101.31 | -- | -- | -- |
| Boundless Bio Inc | 0.00 | -61.76m | 25.07m | 64.00 | -- | 0.2276 | -- | -- | -16.06 | -16.06 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -35.93 | -- | -38.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.22 | -- | -- | -- |
| IGC Pharma Inc | 1.11m | -6.45m | 25.20m | 70.00 | -- | 2.99 | -- | 22.78 | -0.078 | -0.078 | 0.0134 | 0.088 | 0.11 | 0.5489 | 26.02 | 15,800.00 | -64.10 | -51.04 | -81.62 | -56.88 | 46.20 | 43.57 | -582.82 | -1,150.02 | 0.889 | -- | 0.0165 | -- | -5.50 | -20.77 | 45.22 | -- | -35.93 | -- |
| Aeon Biopharma Inc | 0.00 | -3.00k | 25.23m | 5.00 | 0.2156 | -- | 323.40 | -- | 4.87 | 4.87 | 0.00 | -1.71 | 0.00 | -- | -- | 0.00 | -0.0471 | -- | -- | -- | -- | -- | -- | -- | -- | -5.95 | -- | -- | -- | -- | 110.92 | -- | -- | -- |
| Rallybio Corp | 674.00k | -14.17m | 25.35m | 15.00 | -- | 0.3992 | -- | 37.61 | -2.55 | -2.55 | 0.1203 | 12.02 | 0.0092 | -- | -- | 26,960.00 | -19.32 | -40.97 | -21.16 | -43.42 | -- | -- | -2,102.37 | -42,838.52 | -- | -- | 0.00 | -- | -- | -- | 22.52 | -- | -- | -- |
| Marker Therapeutics Inc | 4.69m | -14.30m | 25.84m | 5.00 | -- | 1.41 | -- | 5.50 | -1.23 | -1.23 | 0.3683 | 1.10 | 0.2876 | -- | 3.90 | 938,996.00 | -87.60 | -57.72 | -110.67 | -69.11 | -- | -- | -304.54 | -761.28 | -- | -- | 0.00 | -- | 99.06 | 98.63 | 23.60 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -88.35m | 26.41m | 80.00 | -- | 28.08 | -- | -- | -1.34 | -1.34 | 0.00 | 0.0131 | 0.00 | -- | -- | 0.00 | -136.03 | -58.51 | -184.96 | -64.76 | -- | -- | -- | -- | -- | -- | 0.9482 | -- | -- | -- | -10.93 | -- | -- | -- |
| Cue Biopharma Inc | 7.10m | -37.68m | 26.57m | 41.00 | -- | 1.98 | -- | 3.74 | -0.4553 | -0.4553 | 0.0823 | 0.1703 | 0.1857 | -- | 4.01 | 173,170.70 | -98.58 | -60.20 | -170.74 | -73.56 | -- | -- | -530.75 | -683.99 | -- | -- | 0.1107 | -- | 69.16 | 21.84 | 19.83 | -- | 7.32 | -- |
| Evaxion A/S (ADR) | 7.65m | -5.42m | 26.94m | 46.00 | -- | -- | -- | 3.52 | -16.88 | -16.88 | 2.18 | -- | -- | -- | -- | 166,326.10 | -- | -96.54 | -- | -126.06 | -- | -- | -70.88 | -2,792.25 | -- | -- | -- | -- | 4,480.82 | -- | 52.24 | -- | -- | -- |
| Exicure Inc | 0.00 | -9.23m | 27.47m | 8.00 | -- | 3.97 | -- | -- | -3.07 | -3.07 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -71.27 | -44.45 | -94.78 | -60.08 | -- | -- | -- | -259.52 | -- | -- | 0.00 | -- | -- | -17.34 | 42.65 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 27.48m | 0.00 | -- | -- | -- | -- | -0.0723 | -0.0723 | 0.00 | -0.0644 | 0.00 | -- | -- | -- | -4,831.04 | -- | -- | -- | -- | -- | -- | -- | -- | -86.56 | -- | -- | -- | -- | -13.02 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 0.00 | -1.67m | 27.82m | 26.00 | -- | 3.06 | -- | -- | -0.0041 | -0.0041 | 0.00 | 0.0206 | 0.00 | -- | -- | 0.00 | -7.00 | -20.78 | -19.04 | -43.80 | -- | -- | -- | -1,590.30 | -- | -0.5591 | 0.632 | -- | -100.00 | -- | 42.76 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Aeon Biopharma Inc's reporting currency: US Dollar USD
5.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dauntless Investment Group LLCas of 30 Sep 2025 | 1.13m | 4.68% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 90.53k | 0.38% |
| Geode Capital Management LLCas of 30 Sep 2025 | 47.07k | 0.20% |
| Blue Owl Alternative Credit Advisors LLCas of 30 Sep 2025 | 42.35k | 0.18% |
| StoneX Group, Inc. (Investment Management)as of 30 Sep 2025 | 17.58k | 0.07% |
| XTX Markets LLCas of 30 Sep 2025 | 16.16k | 0.07% |
| Jane Street Capital LLCas of 30 Sep 2025 | 10.42k | 0.04% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 9.70k | 0.04% |
| UBS Securities LLCas of 31 Dec 2025 | 4.05k | 0.02% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.83k | 0.01% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
